A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP
Molecular Therapy · 2024-10 · 32 (10) · 3346-3355
DOI: 10.1016/j.ymthe.2024.08.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024-10. Verfasst von Hector Ribeiro Benatti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Horae Gene Therapy Center, UMass Chan Medical School, 368 Plantation Street, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Cerebellopontine Angle, Green Fluorescent Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Neurological disorders pose a challenge for targeted therapy due to restricted access of therapeutic agents to the central nervous system (CNS). Current methods are limited by procedure-related risks, invasiveness, and insufficient CNS biodistribution. A novel percutaneous transvenous technology, currently in clinical trials for communicating hydrocephalus, offers a minimally invasive approach by providing endovascular access to the cerebrospinal fluid-filled cerebellopontine angle (CPA) cistern. We hypothesized that drug delivery to the CPA cistern could yield widespread CNS distribution. Using an ovine model, we compared the biodistribution of scAAV9-CB-GFP following CPA cistern infusion with previously reported cisterna magna (CM) administration. Targeting both the CPA cistern and CM in sheep, we employed a lumbar spine-inserted microcatheter under fluoroscopy. CPA delivery of AAV9 demonstrated biodistribution and transduction in the cerebral cortices, striatum, thalamus, midbrain, cerebellum, and spinal cord, with minor liver distribution comparable to CM. The favorable safety profile in humans with hydrocephalus suggests that percutaneous endovascular injection into the CPA could offer a clinically safer and minimally invasive delivery system for CNS gene and cell-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Horae Gene Therapy Center, UMass Chan Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
- New England Center for Stroke Research, Department of Radiology, UMass Chan Medical School, 55 N Lake Avenue, Worcester, MA 01655, USA.
- Horae Gene Therapy Center, UMass Chan Medical School, 368 Plantation Street, Worcester, MA 01605, USA; New England Center for Stroke Research, Department of Radiology, UMass Chan Medical School, 55 N Lake Avenue, Worces…
- Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA.
- CereVasc, Inc., 100 1(st) Avenue, Suite 403, Boston, MA 02129, USA.
- Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. Electronic address: adel.malek@tuftsmedicine.org.
Zitieren
APA
Benatti, H. R., Anagnostakou, V., Taghian, T., Hall, E. F., Nath, S., Heilman, C. B., Beneduce, B. M., Leporati, A., Raskett, C., Epshtein, M., King, R., Gounis, M. J., Malek, A. M., & Gray-Edwards, H. L. (2024). A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP. Molecular Therapy, 32(10), 3346-3355. https://doi.org/10.1016/j.ymthe.2024.08.024
Vancouver
Benatti HR, Anagnostakou V, Taghian T, Hall EF, Nath S, Heilman CB, et al. A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP. Molecular Therapy. 2024;32(10):3346-3355. doi:10.1016/j.ymthe.2024.08.024
BibTeX
@article{Benatti2024,
author = {Benatti, Hector Ribeiro and Anagnostakou, Vania and Taghian, Toloo and Hall, Erin F and Nath, Sarah and Heilman, Carl B and Beneduce, Brandon M and Leporati, Anita and Raskett, Christopher and Epshtein, Mark and King, Robert and Gounis, Matthew J and Malek, Adel M and Gray-Edwards, Heather L},
title = {A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP},
journal = {Molecular Therapy},
year = {2024},
volume = {32},
number = {10},
pages = {3346--3355},
doi = {10.1016/j.ymthe.2024.08.024}
}
EUVIMED